BIO CEO & Investor Conference Presentations Target Specific Diseases, Therapies
- Contact: Charles Craig
- Phone: 202-962-9200
Related Content
- 52 Companies To Make Presentations At BIO's Annual CEO & Investor Conference
- Women's Health Issues Explored At BIO CEO & Investor Conference
- CEO & Investor Conference Expected to Attract 1,500 Biotech Leaders and Investors
- BIO Brings Industry Leaders, Investors Together for æ2000 Reasons to Invest in Biotechnology'
(WASHINGTON, D.C., November 11, 1998). . . The Biotechnology Industry Organization (BIO) will host a CEO & Investor Conference in New York Feb. 24-26, 1999, with a format that groups company presentations based on specific diseases and therapeutic approaches.
The conference will be held at the New York Palace Hotel and will be open to the news media. A total of 54 Biotech CEOs will discuss their products and R&D efforts in sessions focused on 12 topics, allowing investors to evaluate complementary and competitive technologies. The CEOs also will participate in separate roundtable discussions on a variety of business issues.
In addition, special guest speakers will include Knight Kiplinger, editor of The Kiplinger Letter and editor-in-chief of Kiplinger'sPersonal Finance Magazine. Mr. Kiplinger's most recent book is "World Boom Ahead."
The company presentation sessions will be one or two hours with a maximum of four CEOs presenting in the shorter sessions and five in the longer ones. Sessions will be moderated by a banker, portfolio manager, pharmaceutical company executive or a clinician.
The 12 session topics will be selected from the following:
- Cancer drugs and immunotherapies
- Drug discovery platforms (genomics, combinatorial
- chemistry)
- Vaccines
- Central nervous system diseases
- Tissue augmentation and engineering
- Genetic diagnostics, pharmacogenomics
- Diabetes
- Transplant directions
- Developmental biology, pharmacogenesis
- Drug delivery
- Gene therapy and antisense
- Infectious diseases
- AIDS and hepatitis
- Agricultural biotechnology products
- Bridging biology with chemistry
- Bridging information technology with biotechnology.
CEO roundtable discussions will focus on:
- Biotechnology's place in the world's stock markets.
- How to create sustainable value from technology platforms.
- Exploring industry consolidation and merger and acquisition strategies.
- How to maximize the value of intellectual property portfolios.
- Creative financing - Case studies.
- New business models for biotechnology.
- European financing opportunities.
For more information contact Charles Craig at BIO in Washington, D.C., at 202-962-9200.
About BIO
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtechNOW.
